{"id":"tipifarnib-zarnestra-r115777","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL289228","moleculeType":"Small molecule","molecularWeight":"489.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting farnesyltransferase, tipifarnib prevents the post-translational modification of Ras proteins, which are often mutated and constitutively active in various cancers. This leads to the inhibition of cell proliferation and induction of apoptosis in cancer cells.","oneSentence":"Tipifarnib is a farnesyltransferase inhibitor that blocks the farnesylation of Ras proteins, which are involved in cell signaling and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:54.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"},{"name":"Basal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06540963","phase":"PHASE2","title":"Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2024-12-06","conditions":"Neuroblastoma","enrollment":98},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":"Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":1376},{"nctId":"NCT04997902","phase":"PHASE1, PHASE2","title":"Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2021-12-07","conditions":"HNSCC","enrollment":45},{"nctId":"NCT04284774","phase":"PHASE2","title":"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-13","conditions":"Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma","enrollment":5},{"nctId":"NCT04809233","phase":"","title":"Expanded Access to Tipifarnib","status":"AVAILABLE","sponsor":"Kura Oncology, Inc.","startDate":"","conditions":"HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)","enrollment":""},{"nctId":"NCT03496766","phase":"PHASE2","title":"Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS","status":"TERMINATED","sponsor":"Spanish Lung Cancer Group","startDate":"2018-05-07","conditions":"Non Small Cell Lung Cancer","enrollment":9},{"nctId":"NCT02779777","phase":"PHASE2","title":"Tipifarnib in Subjects With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"Kura Oncology, Inc.","startDate":"2016-06-01","conditions":"Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT02807272","phase":"PHASE2","title":"Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2017-01-10","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":44},{"nctId":"NCT02383927","phase":"PHASE2","title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2015-05-13","conditions":"Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor","enrollment":63},{"nctId":"NCT02464228","phase":"PHASE2","title":"Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2016-02-25","conditions":"Relapsed or Refractory Peripheral T-Cell Lymphoma","enrollment":65},{"nctId":"NCT03719690","phase":"PHASE2","title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2019-03-15","conditions":"HRAS Gene Mutation, HNSCC","enrollment":296},{"nctId":"NCT00093470","phase":"PHASE3","title":"Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08-18","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":144},{"nctId":"NCT04865159","phase":"PHASE1","title":"Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Kura Oncology, Inc.","startDate":"2021-05-06","conditions":"Advanced Solid Tumor","enrollment":6},{"nctId":"NCT05693090","phase":"PHASE1","title":"Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Kura Oncology, Inc.","startDate":"2023-02-01","conditions":"NSCLC","enrollment":""},{"nctId":"NCT02535650","phase":"PHASE2","title":"Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-11-12","conditions":"Urothelial Carcinoma","enrollment":19},{"nctId":"NCT00470301","phase":"PHASE1, PHASE2","title":"Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-04","conditions":"Breast Cancer, Male Breast Cancer, Stage II Breast Cancer","enrollment":60},{"nctId":"NCT00026104","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-11","conditions":"Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer","enrollment":154},{"nctId":"NCT00050986","phase":"PHASE1, PHASE2","title":"Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-12","conditions":"Glioblastoma Multiforme","enrollment":55},{"nctId":"NCT00077519","phase":"PHASE1","title":"Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2004-01","conditions":"Pancreatic Cancer","enrollment":18},{"nctId":"NCT00082888","phase":"PHASE2","title":"Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-03-24","conditions":"Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":93},{"nctId":"NCT00004009","phase":"PHASE1","title":"R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1999-06","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00025480","phase":"PHASE1","title":"Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2001-08","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT00082810","phase":"PHASE2","title":"Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-03","conditions":"Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer","enrollment":33},{"nctId":"NCT00847223","phase":"PHASE2","title":"Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Lymphoma Study Association","startDate":"2007-06","conditions":"Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT00335764","phase":"PHASE1, PHASE2","title":"Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":92},{"nctId":"NCT00005859","phase":"PHASE1, PHASE2","title":"Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-05-16","conditions":"Brain and Central Nervous System Tumors","enrollment":136},{"nctId":"NCT02210858","phase":"PHASE1, PHASE2","title":"Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-05","conditions":"Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":31},{"nctId":"NCT00085553","phase":"PHASE1","title":"Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05-20","conditions":"Solid Neoplasm","enrollment":29},{"nctId":"NCT00021541","phase":"PHASE2","title":"R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-07-17","conditions":"Neurofibroma, Plexiform, Neurofibromatosis Type I","enrollment":62},{"nctId":"NCT00244972","phase":"PHASE1","title":"Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-10","conditions":"Advanced Malignant Neoplasm","enrollment":74},{"nctId":"NCT00360776","phase":"PHASE2","title":"Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-02","conditions":"Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia","enrollment":25},{"nctId":"NCT00093990","phase":"PHASE3","title":"Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-01","conditions":"Acute Myeloid Leukemia","enrollment":457},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT00005832","phase":"PHASE2","title":"S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2000-06","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT00101153","phase":"PHASE1","title":"Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2007-04","conditions":"Leukemia","enrollment":24},{"nctId":"NCT00047216","phase":"PHASE2","title":"Tipifarnib in Treating Patients With Recurrent Bladder Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2002-11","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT00070252","phase":"PHASE1, PHASE2","title":"Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-09","conditions":"Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma","enrollment":53},{"nctId":"NCT00049387","phase":"PHASE1","title":"Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-09","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":19},{"nctId":"NCT00383474","phase":"PHASE1","title":"Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia","enrollment":35},{"nctId":"NCT01361464","phase":"PHASE2","title":"Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05","conditions":"Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":21},{"nctId":"NCT00972712","phase":"PHASE1","title":"Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":12},{"nctId":"NCT00100750","phase":"PHASE1, PHASE2","title":"Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09","conditions":"Recurrent Breast Carcinoma, Stage IV Breast Cancer","enrollment":31},{"nctId":"NCT02227901","phase":"PHASE1","title":"Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-09","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":19},{"nctId":"NCT00602771","phase":"PHASE2","title":"Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-01","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":84},{"nctId":"NCT00096122","phase":"PHASE1, PHASE2","title":"Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":95},{"nctId":"NCT00281957","phase":"PHASE2","title":"Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-08","conditions":"Recurrent Melanoma, Stage IV Melanoma","enrollment":109},{"nctId":"NCT00079339","phase":"PHASE1, PHASE2","title":"Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01","conditions":"Untreated Childhood Brain Stem Glioma","enrollment":51},{"nctId":"NCT00005845","phase":"PHASE1","title":"Tipifarnib in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes","enrollment":65},{"nctId":"NCT00006376","phase":"PHASE2","title":"R115777 in Treating Patients With Advanced Bladder Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2000-03","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":""},{"nctId":"NCT00361088","phase":"PHASE1, PHASE2","title":"A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT00243035","phase":"PHASE1, PHASE2","title":"Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-08","conditions":"Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":64},{"nctId":"NCT00070525","phase":"PHASE2","title":"Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-11","conditions":"Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma","enrollment":90},{"nctId":"NCT00454480","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2006-08","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":2000},{"nctId":"NCT00005848","phase":"PHASE2","title":"R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2000-04","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT00052728","phase":"PHASE2","title":"Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-12","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00049114","phase":"PHASE2","title":"Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-02","conditions":"Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":62},{"nctId":"NCT00060125","phase":"PHASE2","title":"Tipifarnib in Treating Patients With Metastatic Malignant Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-05","conditions":"Recurrent Melanoma, Stage IV Melanoma","enrollment":40},{"nctId":"NCT00047190","phase":"PHASE2","title":"Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-08","conditions":"Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis","enrollment":35},{"nctId":"NCT00055757","phase":"PHASE2","title":"Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10","conditions":"Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT00124644","phase":"PHASE1","title":"Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2006-03","conditions":"Leukemia","enrollment":30},{"nctId":"NCT00025038","phase":"PHASE2","title":"Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Juvenile Myelomonocytic Leukemia","enrollment":100},{"nctId":"NCT00058097","phase":"PHASE2","title":"Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-08","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":54},{"nctId":"NCT00027872","phase":"PHASE2","title":"Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia","enrollment":125},{"nctId":"NCT00077363","phase":"PHASE2","title":"Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":"Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":70},{"nctId":"NCT00005843","phase":"PHASE2","title":"R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-05","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT00005967","phase":"PHASE1","title":"Tipifarnib in Treating Patients With Advanced Hematologic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-08","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":36},{"nctId":"NCT00005842","phase":"PHASE1","title":"Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Cancer","enrollment":24},{"nctId":"NCT00101296","phase":"PHASE1","title":"Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":30},{"nctId":"NCT00050141","phase":"PHASE2","title":"Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-09","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT00093418","phase":"PHASE2","title":"S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)","enrollment":296},{"nctId":"NCT00045396","phase":"PHASE2","title":"A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":44},{"nctId":"NCT00112853","phase":"PHASE1","title":"Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-03","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)","enrollment":100},{"nctId":"NCT00005041","phase":"PHASE2","title":"R115777 in Treating Patients With Relapsed Small Cell Lung Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1999-09","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00005990","phase":"PHASE1","title":"R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2000-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00012350","phase":"PHASE2","title":"Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2001-01","conditions":"Multiple Myeloma","enrollment":44},{"nctId":"NCT00040105","phase":"PHASE1","title":"Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-10","conditions":"Leukemia, Myeloid, Chronic","enrollment":26},{"nctId":"NCT00054470","phase":"PHASE2","title":"Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2002-12","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00003707","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"1998-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":22},{"nctId":"NCT00005833","phase":"PHASE2","title":"S9923 R115777 in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2000-06","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT00022451","phase":"PHASE1","title":"Tipifarnib in Treating Young Patients With Refractory Leukemia","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2001-06","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00209989","phase":"PHASE2","title":"Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2005-10","conditions":"Glioblastoma Multiforme","enrollment":27},{"nctId":"NCT00005989","phase":"PHASE2","title":"R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2002-11","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00005648","phase":"PHASE3","title":"Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1999-11","conditions":"Pancreatic Neoplasms","enrollment":688},{"nctId":"NCT00354146","phase":"PHASE2","title":"A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-04","conditions":"Leukemia, Nonlymphocytic, Acute","enrollment":252},{"nctId":"NCT00050154","phase":"PHASE2","title":"Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-07","conditions":"Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT00048503","phase":"PHASE2","title":"Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-06","conditions":"Acute Myeloid Leukemia","enrollment":88},{"nctId":"NCT00025454","phase":"PHASE1","title":"R115777 in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2001-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00510939","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2007-03","conditions":"Acute Myeloid Leukemia","enrollment":72},{"nctId":"NCT00210028","phase":"PHASE2","title":"Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Institut Claudius Regaud","startDate":"2003-08","conditions":"Breast Neoplasms","enrollment":40},{"nctId":"NCT00006199","phase":"PHASE1","title":"Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"","conditions":"Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tipifarnib;Zarnestra; R115777","genericName":"Tipifarnib;Zarnestra; R115777","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tipifarnib is a farnesyltransferase inhibitor that blocks the farnesylation of Ras proteins, which are involved in cell signaling and proliferation. Used for Acute myeloid leukemia, Basal cell carcinoma.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}